[New anticoagulants--are we prepared?].
Rivaroxaban and dabigatran are the new anticoagulant drugs--factor Xa and IIa inhibitors. Recently registered in atrial fibrillation and venous thromboembolic disease became the serious competition to other anticoagulants. Blood coagulation parameters do not need to be monitored which can be seen as a huge advantage. At the same time their effectiveness in thromboembolic incidents prevention is comparable and the risk of serious hemorrhage is even lower comparing to therapy with vitamin K antagonists. Concerns arose around the fact that for the time being there is no effective antidote in case of intoxication and no possibility of quick reversal in case of hemorrhage or surgery. The purpose of this paper is to summarize current knowledge regarding the safety of new anticoagulants, and to answer the question--are we really prepared for them?